Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Novo Nordisk===Semaglutide
Entity

Novo Nordisk===Semaglutide

Tracked across 2 events · 40 articles · First seen Mar 03, 2026 · Last active Mar 15, 2026

Sentiment
62
Attention
6
Events
2
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
6 75
Tech
GLP-1 Drugs Show Promise in Addiction Treatment
Novo Nordisk===Semaglutide, a GLP-1 drug, is shown to reduce the risk of developing substance use disorders and mitigate severe outcomes in those already addicted. This expands its potential market beyond diabetes and obesity.
Mar 04, 2026 · 21 articles
4 50
Tech
GLP-1 Drugs Prevent Heart Attack Damage
Novo Nordisk===Semaglutide, another GLP-1 drug, is identified as having potential for repurposing in heart attack recovery, suggesting new applications and market growth.
Mar 03, 2026 · 19 articles
Relationships (2)
Eli Lilly and Company===Tirzepatide ↔ Novo Nordisk===Semaglutide Unknown
United States===VA St. Louis Health Care System ↔ Novo Nordisk===Semaglutide Unknown
NEWSDESK
Track Novo Nordisk===Semaglutide live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.